These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16291893)

  • 1. Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
    van der Linden FA; Kragt JJ; Klein M; van der Ploeg HM; Polman CH; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1677-81. PubMed ID: 16291893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life.
    van der Linden FA; Kragt JJ; Hobart JC; Klein M; Thompson AJ; van der Ploeg HM; Polman CH; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2006 Oct; 77(10):1157-62. PubMed ID: 16820417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
    Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
    Health Technol Assess; 2004 Mar; 8(9):iii, 1-48. PubMed ID: 14982653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
    Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
    Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.
    Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
    Mult Scler; 2003 Aug; 9(4):411-9. PubMed ID: 12926848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The size of the treatment effect: do patients and proxies agree?
    van der Linden FA; Kragt JJ; Hobart JC; Klein M; Thompson AJ; van der Ploeg HM; Polman CH; Uitdehaag BM
    BMC Neurol; 2009 Mar; 9():12. PubMed ID: 19317921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
    Goodwin E; Green C
    Value Health; 2015 Dec; 18(8):1016-24. PubMed ID: 26686786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Validation of selected aspects of psychometry of the Polish version of the Multiple Sclerosis Impact Scale 29 (MSIS-29)].
    Jamroz-Wiśniewska A; Papuć E; Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Stelmasiak Z
    Neurol Neurochir Pol; 2007; 41(3):215-22. PubMed ID: 17629814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis.
    Sonder JM; Holman R; Knol DL; Bosma LV; Polman CH; Uitdehaag BM
    J Neurol Sci; 2013 Nov; 334(1-2):143-7. PubMed ID: 24018128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.
    Sonder JM; Balk LJ; Bosma LV; Polman CH; Uitdehaag BM
    Mult Scler; 2014 Oct; 20(12):1616-23. PubMed ID: 24710798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.
    van der Linden FA; Kragt JJ; van Bon M; Klein M; Thompson AJ; van der Ploeg HM; Polman CH; Uitdehaag BM
    BMC Neurol; 2008 Feb; 8():2. PubMed ID: 18307788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.
    Ramp M; Khan F; Misajon RA; Pallant JF
    Health Qual Life Outcomes; 2009 Jun; 7():58. PubMed ID: 19545445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J; Lamping D; Fitzpatrick R; Riazi A; Thompson A
    Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
    Gray O; McDonnell G; Hawkins S
    Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
    Goodwin E; Green C; Spencer A
    Value Health; 2015 Dec; 18(8):1025-36. PubMed ID: 26686787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
    Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):701-4. PubMed ID: 12438473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales.
    Sonder JM; Bosma LV; van der Linden FA; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Feb; 18(2):196-201. PubMed ID: 21908479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients.
    Rogić Vidaković M; Šimić N; Poljičanin A; Nikolić Ivanišević M; Ana J; Đogaš Z
    Mult Scler Relat Disord; 2021 May; 50():102850. PubMed ID: 33636617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis.
    Learmonth YC; Hubbard EA; McAuley E; Motl RW
    Qual Life Res; 2014 Sep; 23(7):2015-23. PubMed ID: 24526294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.